
Lucence and Waseda University in Japan will develop a liquid biopsy laser-based imaging platform for early cancer detection. The technology captures thousands of high-resolution individual images of circulating tumor cells and clusters from a blood sample.
Lucence believes the technology could be used in potential applications in early cancer detection and disease monitoring. Lucence plans to commercialize the liquid biopsy platform from its CLIA-licensed laboratory in Palo Alto.